Shouyao Holdings (Beijing) Co. Ltd. has disclosed mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1) inhibitors reported to be useful for the treatment of cancer, rheumatoid arthritis, multiple sclerosis, psoriasis, Sjögren’s syndrome, systemic lupus erythematosus, erythema and vasculitis.
Mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1) is an important factor from a complex downstream of Bruton tyrosine kinase (BTK) in the B-cell receptor (BCR) signaling pathway.
Ono Pharmaceutical Co. Ltd. terminated development of CTX-177 (ONO-7018), its ex-oncology candidate in-licensed from Chordia Therapeutics Inc. in December 2020 for up to ¥52.9 billion (US$370.37 million).
Nippon Shinyaku Co. Ltd. has divulged azaindole compounds acting as mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1) inhibitors reported to be useful for the treatment of cancer, multiple sclerosis, rheumatoid arthritis, psoriasis, spinal cord injury, Behçet’s disease, atopic dermatitis and idiopathic pulmonary fibrosis, among others.
Janssen Pharmaceutica NV has divulged mucosa associated lymphoid tissue lymphoma translocation protein 1 (MALT1) inhibitors reported to be useful for the treatment of cancer.
Mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1) is a key regulator of physiological antigen receptor signaling in B cells and T cells, as it is the only component of the MALT1-BCL10-CARD11 (CBM) signalosome with proteolytic activity.
Researchers from Shanghai Institute of Materia Medica of the Chinese Academy of Sciences and affiliated organizations published preclinical data for a new class of mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1) inhibitors being developed as candidates for the treatment of lymphoma.
Hotspot Therapeutics Inc. has identified mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1) inhibitors reported to be useful for the treatment of cancer.
HST-1021 is a novel mucosa-associated lymphoid tissue lymphoma translocation protein (MALT1) allosteric inhibitor identified using the Smart Allostery Platform, and is being developed for the potential treatment of tumors.
Previous studies with mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1) inhibitors have demonstrated their potential as antitumor agents across several tumor models when administered alone or in combination with standard treatments.
